Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Wolstenholme

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Health Economics Review|November 22, 2023
NHS reference costs: a history and cautionary noteBen Amies-Cull, Ramon Luengo-Fernandez, Peter Scarborough, et al.
BMC Health Services Research|July 17, 2019
PRIMEtime CE: a multistate life table model for estimating the cost-effectiveness of interventions affecting diet and physical activityAdam D M Briggs, Linda J Cobiac, Jane Wolstenholme, et al.
BMC Public Health|August 24, 2017
Estimating the variation in need for community-based social care by body mass index in England and associated cost: population-based cross-sectional studyVicky R Copley, Nick Cavill, Jane Wolstenholme, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 1, 2011
Primary care diagnostic technology update: point-of-care testing for glycosylated haemoglobinAnnette Plüddemann, Christopher P Price, Matthew Thompson, et al.
BMJ Open|April 16, 2022
Quality of life, healthcare use and costs in 'at-risk' children after early antibiotic treatment versus placebo for influenza-like illness: within-trial descriptive economic analyses of the ARCHIE randomised controlled trialInes Rombach, Kay Wang, Sharon Tonner, et al.
Bipolar Disorders|June 12, 2014
Economic evaluations in bipolar disorder: a systematic review and critical appraisalAnees Ahmed Abdul Pari, Judit Simon, Jane Wolstenholme, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 28, 2009
Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcomeOliver Rivero-Arias, Melissa Ouellet, Alastair Gray, et al.
Brain and Behavior|September 15, 2021
The costs of bipolar disorder in the United KingdomJudit Simon, Anees A Abdul Pari, Jane Wolstenholme, et al.
Plos One|March 26, 2013
Placebo use in the United kingdom: results from a national survey of primary care practitionersJeremy Howick, Felicity L Bishop, Carl Heneghan, et al.
Journal of Neurology|February 18, 2009
The costs and prognostic characteristics of ischaemic neurological deficit due to subarachnoid haemorrhage in the United Kingdom. Evidence from the MRC International Subarachnoid Aneurysm TrialOliver Rivero-Arias, Jane Wolstenholme, Alastair Gray, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Health Economics Review|November 22, 2023
NHS reference costs: a history and cautionary noteBen Amies-Cull, Ramon Luengo-Fernandez, Peter Scarborough, et al.
BMC Health Services Research|July 17, 2019
PRIMEtime CE: a multistate life table model for estimating the cost-effectiveness of interventions affecting diet and physical activityAdam D M Briggs, Linda J Cobiac, Jane Wolstenholme, et al.
BMC Public Health|August 24, 2017
Estimating the variation in need for community-based social care by body mass index in England and associated cost: population-based cross-sectional studyVicky R Copley, Nick Cavill, Jane Wolstenholme, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 1, 2011
Primary care diagnostic technology update: point-of-care testing for glycosylated haemoglobinAnnette Plüddemann, Christopher P Price, Matthew Thompson, et al.
BMJ Open|April 16, 2022
Quality of life, healthcare use and costs in 'at-risk' children after early antibiotic treatment versus placebo for influenza-like illness: within-trial descriptive economic analyses of the ARCHIE randomised controlled trialInes Rombach, Kay Wang, Sharon Tonner, et al.
Bipolar Disorders|June 12, 2014
Economic evaluations in bipolar disorder: a systematic review and critical appraisalAnees Ahmed Abdul Pari, Judit Simon, Jane Wolstenholme, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 28, 2009
Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcomeOliver Rivero-Arias, Melissa Ouellet, Alastair Gray, et al.
Brain and Behavior|September 15, 2021
The costs of bipolar disorder in the United KingdomJudit Simon, Anees A Abdul Pari, Jane Wolstenholme, et al.
Plos One|March 26, 2013
Placebo use in the United kingdom: results from a national survey of primary care practitionersJeremy Howick, Felicity L Bishop, Carl Heneghan, et al.
Journal of Neurology|February 18, 2009
The costs and prognostic characteristics of ischaemic neurological deficit due to subarachnoid haemorrhage in the United Kingdom. Evidence from the MRC International Subarachnoid Aneurysm TrialOliver Rivero-Arias, Jane Wolstenholme, Alastair Gray, et al.
Pageof 6